D.C. Diagnosis is STAT’s weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox.

First In STAT: CSRxP ups its fight with pharma over R&D

The Campaign for Sustainable Rx Pricing is attacking pharma with a new study, first shared with STAT, that finds 10 of the largest drug makers spent on average 22% of their revenues on research and development in 2017 — a figure the group says proves pharma “is investing more boldly in profits, advertising and corporate overhead than in researching new cures.” The study also provides some interesting new data on how much drug makers spend on advertising and marketing, based on proprietary data from the firm GlobalData. STAT has all the details of the study here, but I wanted to highlight a few data points that caught my eye:

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy